SuperworthNatera profit margin NTRA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2014.
- Net margin, 12 months
- −7.1%
- Operating margin, 12 months
- −10.7%
- Net margin on a year earlier
- +5.8 pts
- Peer median
- 16.8%
Over the twelve months to Jun 30, 2026, Natera kept −7.1% of its revenue as net profit, with an operating margin of −10.7% and a gross margin of 65.2%.
Five years earlier its net margin was −62.3%.
The median for 10 diagnostics and research stocks of a similar size is 16.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −9.0% | −13.4% | 64.7% |
| FY2024 | −11.2% | −13.1% | 60.3% |
| FY2023 | −40.2% | −41.2% | 45.5% |
| FY2022 | −66.8% | −66.0% | 44.4% |
| FY2021 | −75.4% | −74.8% | 49.1% |
| FY2020 | −58.8% | −55.3% | 47.9% |
| FY2019 | −41.3% | −38.5% | 43.3% |
| FY2018 | −49.7% | −44.5% | 35.6% |
| FY2017 | −65.7% | −64.6% | 33.4% |
| FY2016 | −44.1% | −44.4% | 37.5% |
| FY2015 | −36.9% | −31.4% | 40.7% |
| FY2014 | −3.2% | 0.4% | 50.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −7.1% | +5.8 pts | −10.7% | |
| Q1 FY26 | −9.0% | +1.3 pts | −13.0% | |
| Q4 FY25 | −9.0% | +2.2 pts | −13.4% | |
| Q3 FY25 | −14.6% | −0.6 pts | −16.6% | |
| Q2 FY25 | −12.9% | +8.6 pts | −14.9% | |
| Q1 FY25 | −10.4% | +19.9 pts | −12.4% | |
| Q4 FY24 | −11.2% | +28.9 pts | −13.1% | |
| Q3 FY24 | −14.0% | +36.5 pts | −15.8% | |
| Q2 FY24 | −21.5% | +33.5 pts | −23.1% | |
| Q1 FY24 | −30.2% | +32.7 pts | −31.6% | |
| Q4 FY23 | −40.2% | +26.6 pts | −41.2% | |
| Q3 FY23 | −50.5% | +19.8 pts | −50.9% |
Against its peers
Companies in Medical - Diagnostics & Research nearest Natera's size, closest first, today.
| Company | Profit margin |
|---|---|
| NTRANatera | −7.1% |
| AAgilent Technologies | 19.5% |
| IQVIQVIA | 8.1% |
| WATWaters | 3.6% |
| IDXXIDEXX Laboratories | 25.0% |
| ILMNIllumina | 18.4% |
| MTDMettler-Toledo International | 21.9% |
| DGXQuest Diagnostics | 9.2% |
| LHLabcorp | 7.0% |
| DHRDanaher | 15.9% |
| MEDPMedpace | 17.7% |
| Peer median | 16.8% |
Where Natera ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Natera
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.